Ignite Creation Date:
2024-10-26 @ 3:40 PM
Last Modification Date:
2024-10-26 @ 3:40 PM
Study NCT ID:
NCT06605287
Status:
RECRUITING
Last Update Posted:
None
First Post:
2023-05-03
Brief Title:
The Progress of Diabetes After Supaglutide Treatment in Type 2 Diabetes Patients
Sponsor:
None
Organization:
None
Study Overview
Official Title:
A Study to Observe the Progress of Diabetes After Supaglutide Injection for 52 or 28 Weeks Treatment in Type 2 Diabetes Patients
Status:
RECRUITING
Status Verified Date:
2024-08
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
No
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
Glucagon like peptide-1 receptor agonist GLP-1RA can enhance insulin secretion and inhibit glucagon secretion in a glucose concentration dependent manner delay gastric emptying and reduce food intake through central appetite inhibition thus achieving the effect of lowering glucose Supaglutide Injection YN-011 Diabegone has the characteristic of high affinity with GLP-1 receptors Previous studies by Weng Jianping had shown that early use of short-term insulin fortification and oral medication sulfonylureas and metformin fortification therapy for newly diagnosed T2DM still resulted in clinical remission in about 50 of patients one year after discontinuation of medication ie no hypoglycemic drugs were used only diet and exercise therapy were maintained At the same time early fortification therapy can promote pancreatic islets β Cell repair At present there are few studies on the clinical remission rate of diabetes after GLP-1RA hypoglycemic treatment for one year This study aims to discontinue the use of Supaglutide treatment after 52 or 28 weeks and continue a one-year non pharmacological intervention observation to observe the clinical remission rate of diabetes the changes in pancreatic islets β and α cell function insulin resistance body composition and blood glucose fluctuations of patients who stopped using Supaglutide for 3 months and 1 year
Detailed Description:
With the rapid development of economy the occurrence of diabetes in China has also shown a momentum of rapid growth Dietary control and exercise are usually the foundation for treating T2DM For patients whose glucose control does not meet the standard hypoglycemic drugs should be added on the basis of diet control and exercise Glucagon like peptide-1 receptor agonist GLP-1RA can enhance insulin secretion and inhibit glucagon secretion in a glucose concentration dependent manner delay gastric emptying and reduce food intake through central appetite inhibition thus achieving the effect of lowering glucose Supaglutide Injection YN-011 Diabegone has the characteristic of high affinity with GLP-1 receptors Supaglutide can activate GLP-1 receptor in pancreatic islets β cells to increase insulin secretion and inhibit glucagon release in a glucose dependent manner Previous studies by Weng Jianping had shown that early use of short-term insulin fortification and oral medication sulfonylureas and metformin fortification therapy for newly diagnosed T2DM still resulted in clinical remission in about 50 of patients one year after discontinuation of medication ie no hypoglycemic drugs were used only diet and exercise therapy were maintained At the same time early fortification therapy can promote pancreatic islets β Cell repair At present there are few studies on the clinical remission rate of diabetes after GLP-1RA hypoglycemic treatment for one year This study aims to discontinue the use of Supaglutide treatment after 52 or 28 weeks and continue a one-year non pharmacological intervention observation to observe the clinical remission rate of diabetes pancreatic islets β and α cell function insulin resistance changes in body composition and blood glucose fluctuations of patients who stopped using Supaglutide for 3 months and 1 year
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
None
Is a FDA Regulated Device?:
None
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None